Iqymune (Human Normal Immunoglobulin)

Human normal immunoglobulin provides a broad spectrum of pooled IgG antibodies that bind to pathogens, toxins, and immune complexes. By neutralising these targets and engaging Fc receptors, it delivers passive immunity and exerts immunomodulatory effects, such as down‑regulating inflammatory cytokines and complement activation, thereby restoring immune balance.

The dose of Iqymune is individualized and set by the prescribing healthcare professional based on the patient’s weight, severity of the immunodeficiency, clinical response, and laboratory parameters. Dosing regimens may vary between acute replacement therapy and chronic maintenance, and adjustments are made according to tolerance and therapeutic goals.

The pregnancy safety category for Iqymune is listed as unknown. Use during pregnancy or lactation should only occur when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should evaluate each case carefully and discuss potential risks with the patient.

To order Iqymune, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, cold‑chain shipping details and any necessary import documentation.

Iqymune is comparable to other intravenous immunoglobulin (IVIG) preparations in providing pooled IgG antibodies for immune replacement and modulation. Differences among products may include manufacturing processes, stabilisers, IgG subclass distribution, and approved indications. Clinicians select a specific IVIG based on efficacy, safety profile, tolerability, and logistical considerations such as supply chain and storage requirements.

Iqymune must be stored at 2‑8 °C (refrigerated) in its original container. It should be protected from light, kept upright, and must not be frozen or shaken. Any deviation from these conditions can affect product stability and potency, so proper cold‑chain handling is essential throughout distribution and use.

Iqymune is administered by intravenous infusion under medical supervision. The infusion rate is typically started slowly and may be increased as tolerated, following the prescribing information. Vital signs are monitored before, during, and after the infusion to detect any adverse reactions promptly.

Serious risks include aseptic meningitis, thromboembolic events, acute renal failure, and severe allergic reactions such as anaphylaxis. Patients with known IgA deficiency, renal impairment, or a history of clotting disorders require careful assessment before treatment, and immediate medical attention is needed if any severe symptoms develop.

Iqymune is contraindicated in individuals with a known severe IgA deficiency who have experienced anaphylactic reactions to immunoglobulin products, and in patients with a documented hypersensitivity to any component of the formulation. Caution is also advised for those with uncontrolled renal disease or active thrombotic disorders.